+58%

est. 2Y upside i

HealthcareSeries A

Rank

#1446

Sector

HealthTech

Est. Liquidity

~5Y

Data Quality

Data: Low

Agebold offers a real but highly speculative equity story for a job candidate entering at Series A stage: the Medicare Advantage channel and $80B TAM are genuine structural tailwinds, but missing YoY growth data, an estimated $27M preference stack against a ~$90M implied valuation, and a 5+ year probable time to liquidity make this a high-variance bet.

Last updated: May 14, 2026

Bull (18%)+300%

Agebold wins 5+ Medicare Advantage plan contracts beyond UnitedHealthcare Renew Active, scaling revenue to $30M+ by 2028–2029 and attracting a strategic acquisition at ~$350–450M (roughly 10x revenue) from a large insurer or health system looking to own the fall-prevention category. The Forbes-validated $80B market narrative and documented clinical outcomes convert the Medicare cost-reduction ROI story into a premium exit, clearing the $27M preference stack and delivering strong common-stock returns.

Base (57%)+40%

Agebold raises a Series B at a modest premium to its estimated ~$90M Series A post-money valuation, growing revenue to $12–15M on 2–3 additional Medicare Advantage partnerships and steady D2C subscriptions over 4–5 years. Common equity appreciates in paper value, but the $27M preference overhang plus Series B dilution of ~15–20% limits realized employee upside to roughly 30–50% above grant price, with no near-term liquidity.

Bear (25%)-75%

Medicare Advantage procurement stalls, the UnitedHealthcare Renew Active contract does not renew at scale, and D2C revenue plateaus below cash breakeven, forcing a down round or distressed acquisition below the $27M liquidation preference stack. Common stockholders receive little to nothing after preferred investors are made whole, consistent with the Series A bear floor of -70% to -90%.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

3000%

$27M in total liquidation preferences against an estimated ~$90M Series A post-money implied valuation means investors recoup roughly 30 cents of every dollar in any exit before common shareholders see proceeds.

Dilution Risk

high

As a Series A company likely 2–3 funding rounds from exit, each future raise (Series B est. 15–20% dilution, Series C est. 10–15%) will cumulatively dilute current common equity by 25–35%+ before any liquidity event.

Secondary Liquidity

none

No secondary market exists for Agebold common stock at this stage; all employee equity is fully illiquid until a company-level exit event estimated 5+ years out.

Other — 9 roles

View all 9 open roles at Agebold →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Agebold's data — designed to show you've done your homework.

  • 1

    “What is the current Medicare Advantage pipeline — how many plan RFPs are in active procurement, and what does the typical contract value and sales cycle length look like versus the UHC deal?”

  • 2

    “How does revenue split between direct-to-consumer subscriptions and B2B Medicare plan contracts today, and what are the respective net revenue retention and churn rates for each channel?”

  • 3

    “Can you walk me through the current cap table — specifically total shares outstanding, the full liquidation preference stack across all rounds, and at what exit valuation common stock begins to meaningfully participate?”

Community

Valuation Sentiment

Our model estimates +58% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.